Growth plates are the key distinction
Long bones lengthen at growth plates during development. The NIDDK’s acromegaly booklet explains that these plates fuse after puberty, so excess growth hormone in adults does not increase height. A marketing explanation that stops at “stimulates growth hormone” leaves out this essential anatomical limit.
This makes the status of skeletal growth more relevant than a seller’s age cutoff. Someone concerned about delayed puberty or incomplete growth needs an individual medical assessment. A birthday, a low hormone number, or a photograph cannot settle that question. It would also be misleading to turn the possibility of an unusual developmental situation into a general promise that adults can gain several inches.
Childhood treatment cannot answer an adult question
A study involving children who are still growing asks a different question from one involving adults with mature skeletons. Even if a treatment affects childhood growth, that observation does not demonstrate that the same treatment lengthens adult bones. The starting biology and the intended outcome differ.
When a height advertisement cites a paper, check the participants’ ages, diagnoses, exact treatment, and skeletal maturity. Ask whether final adult height was actually measured or whether the paper reported a shorter-term growth rate. Also identify the drug: a growth hormone study is not automatically a sermorelin study. These distinctions are necessary before considering the result, rather than details that can be filled in after accepting the advertisement’s conclusion.
More tissue growth is not the same as more height
NIDDK describes acromegaly as a condition involving excessive growth hormone, with enlargement of tissues such as the hands, feet, and facial structures. Those changes illustrate why “growth” in an adult is not synonymous with beneficial height gain. The condition also has important health consequences.
This background does not establish that a particular sermorelin prescription causes acromegaly or quantify a patient’s risk. It explains why deliberately pursuing ever-higher hormone levels is not a reasonable height strategy. A changing shoe or ring size is not proof that a height program is working. Report unexplained physical changes to a clinician, including your complete medication list, rather than treating them as a milestone to encourage.
Read before-and-after claims carefully
A difference between two height measurements does not, by itself, identify what caused it. Before-and-after photographs are especially poor evidence when posture, footwear, camera position, or measurement technique differ. A testimonial may accurately describe what someone believes happened while still failing to establish treatment-related bone growth.
Ask a seller for research that measures the claimed outcome in the population being targeted. An IGF-1 result cannot substitute for measured height, and a bone-density result answers another question entirely. Our bone-density guide separates those outcomes. If the evidence supplied never addresses adult height, the promise remains unsupported by that evidence, however detailed the explanation of the hormone pathway sounds.
Use the consultation to clarify the actual concern
If height or a recent change in height concerns you, explain the timeline, previous measurements, and any relevant growth or endocrine history to a clinician. A new loss of height and a wish to become taller are different clinical questions. Ask what assessment is appropriate before considering a hormone treatment sold for a cosmetic goal.
FDA explains that compounded drugs are not FDA-approved. A prescription or custom preparation does not establish an adult-height benefit. For a proposed treatment, ask the clinician to state its actual purpose and the evidence supporting that purpose. A useful answer should address your concern directly without turning uncertainty about growth into a guarantee.